Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116) / 医学前沿
Frontiers of Medicine
; (4): 1068-1079, 2023.
Article
de En
| WPRIM
| ID: wpr-1010829
Bibliothèque responsable:
WPRO
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic agents that target severe acute respiratory syndrome coronavirus 2 to control viral infection. So far, a few small-molecule antiviral drugs, including nirmatrelvir-ritonavir (Paxlovid), remdesivir, and molnupiravir have been marketed for the treatment of COVID-19. Nirmatrelvir-ritonavir has been recommended by the World Health Organization as an early treatment for outpatients with mild-to-moderate COVID-19. However, the existing treatment options have limitations, and effective treatment strategies that are cost-effective and convenient for tackling COVID-19 are still needed. To date, four domestically developed oral anti-COVID-19 drugs have been granted conditional market approval in China. These drugs include azvudine, simnotrelvir-ritonavir (Xiannuoxin), leritrelvir, and mindeudesivir (VV116). Preclinical and clinical studies have explored the efficacy and tolerability of mindeudesivir and supported its early use in mild-to-moderate COVID-19 cases at high risk for progression. In this review, we discuss the most recent findings regarding the pharmacological mechanism and therapeutic effects focusing on mindeudesivir and other small-molecule antiviral agents for COVID-19. These findings will expand our understanding and highlight the potential widespread application of China's homegrown anti-COVID-19 drugs.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Antiviraux
/
Proline
/
Adénosine
/
Chine
/
Ritonavir
/
COVID-19
/
Lactames
/
Leucine
/
Nitriles
Limites du sujet:
Humans
Pays comme sujet:
Asia
langue:
En
Texte intégral:
Frontiers of Medicine
Année:
2023
Type:
Article